Learn how to leverage PTEN and ERG testing as a prognostic marker for more
In November, Inform Diagnostics (MLS) will offer a series of webinars
demonstrating the value of molecular markers, such as PTEN and ERG, in
diagnosing prostate cancer. PTEN loss correlates with more advanced stage
of prostate cancer, making it a prognostic marker for more aggressive
cancers. PTEN is a key tumor suppressor gene in prostate cancer, and deletion
of PTEN occurs in up to 50-70% of advanced prostate tumors.
These molecular markers offer additional insight beyond what a traditional
prostate biopsy can provide.
- PTEN is a prognostic marker that helps to identify indolent versus aggressive
- Combined PTEN loss and ERG overexpression status are indicators of aggressive disease
- ERG overexpression is 98.1% specific to adenocarcinoma, aiding in a more
- ERG positive High Grade PIN suggests a need for a subsequent biopsy
We know the importance of accurate, timely results, and our commitment
is to give you the information you need to provide the right answer to
your patients. Free webinars are offered at the following times:
According to the American Cancer Society (ACS), prostate cancer is the
second most common cancer in men, with one case diagnosed in every six
men. The ACS estimates about 240,000 men will be diagnosed with the disease in 2013.
About Inform Diagnostics
Serving more than 3,500 patients each day,
Inform Diagnostics is a leader in providing an academic-caliber pathology laboratory with
diagnostic services in the fields of dermatology, gastroenterology, hematology
and urology. Building upon our experience with health IT, we also offer
accessible technology solutions to assist healthcare professionals as
they work towards accordance with Meaningful Use initiatives.
Inform Diagnostics, a wholly-owned subsidiary of Japan-based Inform Diagnostics Holdings
Inc., employs a talented team of leading pathologists, histologists, lab
technicians, technology consultants, and other medical professionals —
all driven to help provide the highest and most up-to-date levels of diagnostic
quality, enhanced workflow and practice solutions possible. It is part
of our commitment: not only to scientific excellence, but to patients